

Sanam Loghavi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1907007/publications.pdf>

Version: 2024-02-01

171
papers

5,380
citations

117453

34
h-index

110170

64
g-index

174
all docs

174
docs citations

174
times ranked

5006
citing authors

#	ARTICLE	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	3.3	1,211
2	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. <i>Blood</i> , 2020, 135, 791-803.	0.6	412
3	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. <i>Nature Communications</i> , 2020, 11, 5327.	5.8	208
4	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	0.8	173
5	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	2.5	106
6	Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. <i>Journal of Hematology and Oncology</i> , 2015, 8, 65.	6.9	102
7	Intrauterine Growth Restriction Caused by Underlying Congenital Cytomegalovirus Infection. <i>Journal of Infectious Diseases</i> , 2014, 209, 1573-1584.	1.9	95
8	Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. <i>Journal of Hematology and Oncology</i> , 2014, 7, 74.	6.9	90
9	<i>DDX41</i> mutations in myeloid neoplasms are associated with male gender, <i>TP53</i> mutations and high-risk disease. <i>American Journal of Hematology</i> , 2019, 94, 757-766.	2.0	86
10	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 25.	2.8	85
11	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e29-e37.	2.2	84
12	Outcomes of <i>TP53</i> mutant acute myeloid leukemia with decitabine and venetoclax. <i>Cancer</i> , 2021, 127, 3772-3781.	2.0	80
13	Chemokine-Like Receptor-1 Expression by Central Nervous System-Infiltrating Leukocytes and Involvement in a Model of Autoimmune Demyelinating Disease. <i>Journal of Immunology</i> , 2009, 183, 6717-6723.	0.4	70
14	Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. <i>Haematologica</i> , 2017, 102, 1661-1670.	1.7	64
15	Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. <i>Blood Cancer Journal</i> , 2019, 9, 7.	2.8	64
16	Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1429-1437.	2.1	59
17	B-Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2015, 144, 393-410.	0.4	56
18	Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 305-311.	1.7	56

#	ARTICLE	IF	CITATIONS
19	Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. <i>Modern Pathology</i> , 2014, 27, 1468-1478.	2.9	54
20	MYC protein expression is an important prognostic factor in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 37-48.	0.6	54
21	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	2.6	50
22	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2022, 12, 10.	2.8	48
23	Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. <i>Leukemia and Lymphoma</i> , 2016, 57, 2804-2812.	0.6	46
24	<i>TP53</i> copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. <i>Blood</i> , 2022, 140, 58-72.	0.6	46
25	Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. <i>Human Pathology</i> , 2015, 46, 558-569.	1.1	43
26	<i>TP53</i> overexpression is an independent adverse prognostic factor in <i>de novo</i> myelodysplastic syndromes with fibrosis. <i>British Journal of Haematology</i> , 2015, 171, 91-99.	1.2	43
27	Prognostic impact of <i>CD5</i> expression in diffuse large B-cell lymphoma in patients treated with rituximab+ <i>EPOCH</i> . <i>European Journal of Haematology</i> , 2017, 98, 415-421.	1.1	41
28	Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. <i>Blood</i> , 2021, 138, 371-371.	0.6	41
29	Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. <i>Leukemia and Lymphoma</i> , 2016, 57, 1104-1113.	0.6	40
30	Mutational landscape of myelodysplastic/myeloproliferative neoplasm "unclassifiable". <i>Blood</i> , 2018, 132, 2100-2103.	0.6	40
31	Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , 2021, 106, 1047-1055.	1.7	40
32	Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1036-1043.	2.0	38
33	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3 internal tandem duplication mutation positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766.	2.0	38
34	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. <i>Haematologica</i> , 2021, 106, 1120-1128.	1.7	37
35	CINtec PLUS dual immunostain: A triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion. <i>Diagnostic Cytopathology</i> , 2013, 41, 582-587.	0.5	36
36	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. <i>Blood Advances</i> , 2021, 5, 2173-2183.	2.5	35

#	ARTICLE	IF	CITATIONS
37	Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of $\hat{I}^{\beta 1}$ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With $\hat{I}^{\beta 1}$ T-Cell Large Granular Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2015, 144, 607-619.	0.4	34
38	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. <i>Blood Advances</i> , 2018, 2, 1807-1816.	2.5	34
39	A phase 1b/2 study of azacitidine with PD $\hat{\epsilon}$ L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771.	2.0	34
40	Hypomethylating agent and venetoclax with FLT3 inhibitor $\hat{\epsilon}$ triplet $\hat{\epsilon}$ therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	2.8	33
41	Prognostic significance of baseline <i>c</i> >FLT3</i> $\hat{\epsilon}$ TD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	2.0	32
42	Epstein $\hat{\epsilon}$ Barr virus $\hat{\epsilon}$ positive plasmacytoma in immunocompetent patients. <i>Histopathology</i> , 2015, 67, 225-234.	1.6	31
43	Venetoclax combined with <i>sc</i> >FLAG $\hat{\epsilon}$ IDA</i> induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	2.0	31
44	Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. <i>American Journal of Surgical Pathology</i> , 2018, 42, 799-806.	2.1	29
45	Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. <i>Oncotarget</i> , 2018, 9, 10259-10271.	0.8	29
46	A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 367-379.	2.9	29
47	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
48	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. <i>Modern Pathology</i> , 2015, 28, 373-382.	2.9	28
49	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with <i>c</i> >NPM1</i> $\hat{\epsilon}$ mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1054-1063.	1.2	28
50	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1075-1079.	0.7	27
51	Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. <i>Oncotarget</i> , 2018, 9, 8441-8449.	0.8	27
52	Durable remission with rituximab in a patient with an unusual variant of <i>sc</i> >C</i>astleman's disease with myelofibrosis $\hat{\epsilon}$ <i>sc</i> >TAFRO</i> syndrome. <i>American Journal of Hematology</i> , 2015, 90, 1091-1092.	2.0	26
53	Association of gene mutations with time $\hat{\epsilon}$ to $\hat{\epsilon}$ first treatment in 384 treatment $\hat{\epsilon}$ naive chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2019, 187, 307-318.	1.2	26
54	Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2019, 134, 678-678.	0.6	26

#	ARTICLE	IF	CITATIONS
55	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. <i>Nature Medicine</i> , 2022, 28, 557-567.	15.2	26
56	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	2.2	26
57	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia ⁺ cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150.	2.0	25
58	Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1670-1677.	2.5	24
59	Myeloid neoplasms with concurrent <i>BCR-ABL1</i> and <i>CBFB</i> rearrangements: A series of 10 cases of a clinically aggressive neoplasm. <i>American Journal of Hematology</i> , 2017, 92, 520-528.	2.0	23
60	Ultra-Rapid Reporting of GENomic Targets (URGENTseq). <i>Journal of Molecular Diagnostics</i> , 2019, 21, 89-98.	1.2	23
61	Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. <i>Leukemia</i> , 2022, 36, 1343-1350.	3.3	23
62	Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. <i>Blood</i> , 2015, 125, 3360-3363.	0.6	22
63	Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent <i>CD33</i> expression and <i>in vitro</i> response to targeted <i>CD33</i> therapy. <i>British Journal of Haematology</i> , 2019, 186, 538-548.	1.2	21
64	Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1235-1243.	2.1	21
65	High-grade Transformation of Low-grade B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, e1-e16.	2.1	19
66	Routine sequencing in <i>CLL</i> has prognostic implications and provides new insight into pathogenesis and targeted treatments. <i>British Journal of Haematology</i> , 2019, 185, 852-864.	1.2	19
67	Decitabine and venetoclax for <i>IDH1/2</i> mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E154-E157.	2.0	19
68	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1733-1739.	0.6	19
69	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. <i>Annals of Diagnostic Pathology</i> , 2019, 41, 38-42.	0.6	18
70	CAL2 Immunohistochemical Staining Accurately Identifies <i>CALR</i> Mutations in Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2016, 146, 431-438.	0.4	17
71	Chronic lymphoproliferative disorder of NK cells: A single institution review with emphasis on relative utility of multimodality diagnostic tools. <i>European Journal of Haematology</i> , 2018, 100, 444-454.	1.1	17
72	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with <i>FLT3</i> internal tandem duplication and worse relapse-free survival. <i>American Journal of Hematology</i> , 2018, 93, 1376-1383.	2.0	17

#	ARTICLE	IF	CITATIONS
73	NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E158-E160.	2.0	17
74	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. <i>Modern Pathology</i> , 2020, 33, 1678-1689.	2.9	16
75	Discovery of imatinib-responsive FIP1L1-PDGFR α mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2014, 7, 26.	6.9	15
76	Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 74.	6.9	15
77	Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 509-516.	1.2	15
78	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 492-499.	2.1	14
79	A multimodality workup of patients with Hypereosinophilia. <i>American Journal of Hematology</i> , 2018, 93, 1337-1346.	2.0	14
80	Immunopathology of Kikuchi-Fujimoto disease: A reappraisal using novel immunohistochemistry markers. <i>Histopathology</i> , 2020, 77, 262-274.	1.6	14
81	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. <i>Blood</i> , 2019, 134, 2723-2723.	0.6	14
82	Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 358-367.	1.2	13
83	Emergence of BCR-ABL1 Fusion in AML Post FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series. <i>Frontiers in Oncology</i> , 2020, 10, 588876.	1.3	13
84	Systematic use of fluorescence in situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms. <i>Histopathology</i> , 2020, 76, 1042-1054.	1.6	13
85	The Implementation and Effectiveness of PathElective.com. <i>Academic Pathology</i> , 2021, 8, 23742895211006829.	0.7	13
86	Immunophenotypic Shifts in Primary Cutaneous T-Cell Lymphoma Suggest Antigenic Modulation. <i>American Journal of Surgical Pathology</i> , 2017, 41, 431-445.	2.1	12
87	Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature. <i>Histopathology</i> , 2017, 70, 821-831.	1.6	12
88	PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2019, 11, 695.	1.7	12
89	Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. <i>Modern Pathology</i> , 2021, 34, 1143-1152.	2.9	12
90	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 865-876.	2.0	12

#	ARTICLE	IF	CITATIONS
91	Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases. <i>Annals of Diagnostic Pathology</i> , 2016, 21, 53-58.	0.6	11
92	Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. <i>Human Pathology</i> , 2018, 82, 215-231.	1.1	11
93	Polyomavirus infection and urothelial carcinoma. <i>Diagnostic Cytopathology</i> , 2011, 39, 531-535.	0.5	10
94	Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. <i>Blood</i> , 2017, 129, 1563-1563.	0.6	10
95	Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. <i>Blood Cancer Journal</i> , 2020, 10, 86.	2.8	10
96	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 Δ ITD and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390.	2.0	10
97	Development of TP53 mutations over the course of therapy for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1420-1428.	2.0	10
98	Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. <i>Modern Pathology</i> , 2022, 35, 1212-1219.	2.9	10
99	RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyperCVAD. <i>Cancer Medicine</i> , 2020, 9, 849-858.	1.3	9
100	Social Media for Hematopathologists: Medical Practice Reinvented? #Hemepath. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 383-390.	1.2	9
101	Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. <i>Modern Pathology</i> , 2021, 34, 854-861.	2.9	9
102	Clonal haematopoiesis of emerging significance. <i>Pathology</i> , 2021, 53, 300-311.	0.3	9
103	T-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL. <i>British Journal of Haematology</i> , 2021, 194, 1034-1038.	1.2	9
104	Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 1309-1309.	0.6	9
105	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. <i>Blood Advances</i> , 2020, 4, 5716-5721.	2.5	9
106	Clinical Validation of a Multipurpose Assay for Detection and Genotyping of CALR Mutations in Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2015, 144, 746-755.	0.4	8
107	Characterization of chronic myelomonocytic leukemia with TP53 mutations. <i>Leukemia Research</i> , 2018, 70, 97-99.	0.4	8
108	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E50-E53.	2.0	8

#	ARTICLE	IF	CITATIONS
109	Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 370-376.	1.3	8
110	Dopamine receptor mechanism(s) and antinociception and tolerance induced by swim stress in formalin test. <i>Behavioural Pharmacology</i> , 2006, 17, 341-347.	0.8	7
111	Disseminated blastic plasmacytoid dendritic cell neoplasm. <i>Blood</i> , 2015, 126, 558-558.	0.6	7
112	<i>De novo</i> CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. <i>Leukemia and Lymphoma</i> , 2020, 61, 328-336.	0.6	7
113	Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. <i>American Journal of Clinical Pathology</i> , 2016, 145, 418-427.	0.4	6
114	3q26/ EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. <i>Leukemia Research</i> , 2018, 65, 25-28.	0.4	6
115	Recent Updates on Chronic Myelomonocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 446-454.	1.2	6
116	Histology of the normal ovary in premenopausal patients. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151475.	0.6	6
117	Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. <i>Modern Pathology</i> , 2021, 34, 300-313.	2.9	6
118	t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. <i>Annals of Hematology</i> , 2020, 99, 487-500.	0.8	6
119	Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. <i>Blood</i> , 2018, 132, 84-84.	0.6	6
120	Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. <i>Blood</i> , 2021, 138, 370-370.	0.6	6
121	Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. <i>Aesthetic Surgery Journal</i> , 2018, 38, .	0.9	5
122	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. <i>Cancer</i> , 2021, 127, 3113-3124.	2.0	5
123	Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. <i>Blood</i> , 2021, 138, 798-798.	0.6	5
124	Unusual breast mass: lymphoma with crystal-storing histiocytosis. <i>Blood</i> , 2015, 125, 2445-2445.	0.6	4
125	How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 787-792.	2.3	4
126	Characteristics and clinical implications of reactive germinal centers in the bone marrow. <i>Human Pathology</i> , 2017, 68, 7-21.	1.1	4

#	ARTICLE	IF	CITATIONS
127	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline <i>RUNX1</i> mutations. <i>American Journal of Hematology</i> , 2020, 95, E313-E315.	2.0	4
128	Future of Education or Present Reality?. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1350-1354.	1.2	4
129	A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1300-1304.	2.3	4
130	Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 701-701.	0.6	4
131	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	2.0	4
132	Multimodality Evaluation of a Rare Intracardiac Tumor: Cardiac Hemangioma. <i>American Journal of Medicine</i> , 2011, 124, e3-e4.	0.6	3
133	<i>DNMT3A</i> , <i>TET2</i> , and <i>JAK2</i> mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1969-1973.	0.6	3
134	Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. <i>Leukemia and Lymphoma</i> , 2020, 61, 3243-3246.	0.6	3
135	FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. <i>American Journal of Hematology</i> , 2021, 96, E275-E279.	2.0	3
136	Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. <i>Leukemia and Lymphoma</i> , 2021, 62, 3296-3299.	0.6	3
137	Quantitative PCR for Plasma Epstein-Barr Virus Loads in Cancer Diagnostics. <i>Methods in Molecular Biology</i> , 2016, 1392, 51-61.	0.4	3
138	A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation. <i>Blood</i> , 2021, 138, 4436-4436.	0.6	3
139	Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, e10-e13.	1.2	2
140	Marked paraneoplastic leukemoid reaction in a patient with mesothelioma mimicking a myeloid neoplasm. <i>Blood</i> , 2020, 135, 457-457.	0.6	2
141	Ovarian mucinous neoplasms, intestinal type, in premenopausal patients, develop in abnormal ovaries. <i>Human Pathology</i> , 2021, 108, 32-41.	1.1	2
142	Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. <i>British Journal of Haematology</i> , 2021, 192, 667-671.	1.2	2
143	Hematogones with light chain restriction: A potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens. <i>Leukemia Research</i> , 2021, 111, 106704.	0.4	2
144	Elevating Twitter-Based Journal Club Discussions by Leveraging a Voice-Based Platform: #HemepathJC Meets Clubhouse. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 418-421.	1.2	2

#	ARTICLE	IF	CITATIONS
145	Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. <i>Blood</i> , 2018, 132, 3983-3983.	0.6	2
146	Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. <i>American Journal of Dermatopathology</i> , 2018, 40, 831-835.	0.3	1
147	Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms. <i>Surgical Pathology Clinics</i> , 2019, 12, 651-669.	0.7	1
148	Chronic Myelomonocytic Leukemia: Hematopathology Perspective. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 142-149.	0.6	1
149	Posttransplant Lymphoproliferative Disorder Involving the Gastrointestinal Tract. <i>Journal of Digestive Endoscopy</i> , 2020, 11, 293-294.	0.1	1
150	Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML. <i>Blood</i> , 2021, 138, 607-607.	0.6	1
151	<sc>Non-coding </i>NOTCH1</sc> mutations in chronic lymphocytic leukemia negatively impact prognosis. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
152	Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2022, 116, 106827.	0.4	1
153	Major Clinical Response in a Patient with Leukemia Cutis Treated with the Bromodomain Inhibitor PLX51107 and Azacitidine. <i>Leukemia Research</i> , 2022, 119, 106884.	0.4	1
154	Myeloproliferative Neoplasms with Calreticulin Mutations Exhibit Distinctive Morphologic Features. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S57.	0.2	0
155	A rare histologic variant of a common lymphoma. <i>Blood</i> , 2016, 128, 3012-3012.	0.6	0
156	Mixed Cytoses and Cytopenias. , 2018, , 257-279.		0
157	Patient with mixed-phenotype acute leukemia with CFBF rearrangement. <i>Leukemia and Lymphoma</i> , 2019, 60, 2829-2831.	0.6	0
158	MPN-402: Delayed Resolution of Bone Marrow Morphological Changes of Myelofibrosis Following Successful Stem Cell Transplant and Molecular Clearance of Disease: A Cautionary Tale. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S340-S341.	0.2	0
159	Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis â€” Chronic Myelomonocytic Leukemia and Beyond. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 286-303.	1.2	0
160	Poster: AML-204: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S213.	0.2	0
161	AML-291: Treatment Response and Outcome in DNMT3A-mutated Acute Myeloblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S301-S302.	0.2	0
162	Clinical and Biological Features of Primary Testicular B-Cell Lymphoma - a Single-Institution Study of 89 Cases. <i>Blood</i> , 2014, 124, 3036-3036.	0.6	0

#	ARTICLE	IF	CITATIONS
163	MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes. <i>Blood</i> , 2014, 124, 5334-5334.	0.6	0
164	RAS and TP53, Not NOTCH1, Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad. <i>Blood</i> , 2018, 132, 4085-4085.	0.6	0
165	Expression Profiling of mRNA By Next Generation Sequencing and the Development of Algorithm for Predicting Response in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1314-1314.	0.6	0
166	Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2730-2730.	0.6	0
167	Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2374-2374.	0.6	0
168	Outcomes in Advanced-Stage Plasmablastic Lymphoma. <i>Blood</i> , 2021, 138, 2519-2519.	0.6	0
169	NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 2287-2287.	0.6	0
170	Essential thrombocythemia complicating hemoglobin SC disease and presenting with priapism. <i>Blood</i> , 2022, 139, 2258-2258.	0.6	0
171	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. <i>Modern Pathology</i> , 0, , .	2.9	0